Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia LoRusso

Showing results (121-130 of 164) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2019
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid TumorsSarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, et al.
Investigational New Drugs|November 28, 2017
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trialEmiliano Calvo, Analia Azaro, Jordi Rodon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsDavid S Hong, Patricia LoRusso, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|March 13, 2025
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancerOladapo O Yeku, Minal Barve, Winston W Tan, et al.
British Journal of Clinical Pharmacology|August 1, 2020
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumoursDarcy B Pooler, Dylan B Ness, John Sarantopoulos, et al.
Investigational New Drugs|April 25, 2022
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human studyPatricia LoRusso, Mark J Ratain, Toshihiko Doi, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
Cancer Research Communications|June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Pageof 17

Showing results (121-130 of 164) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2019
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid TumorsSarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, et al.
Investigational New Drugs|November 28, 2017
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trialEmiliano Calvo, Analia Azaro, Jordi Rodon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsDavid S Hong, Patricia LoRusso, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|March 13, 2025
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancerOladapo O Yeku, Minal Barve, Winston W Tan, et al.
British Journal of Clinical Pharmacology|August 1, 2020
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumoursDarcy B Pooler, Dylan B Ness, John Sarantopoulos, et al.
Investigational New Drugs|April 25, 2022
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human studyPatricia LoRusso, Mark J Ratain, Toshihiko Doi, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
Cancer Research Communications|June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Pageof 17